Cresco Labs OTC ( (CRLBF) ) has released its Q3 earnings. Here is a breakdown of the information Cresco Labs OTC presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cresco Labs Inc. is a leading company in the cannabis industry, known for its branded cannabis products and Sunnyside dispensaries, operating across multiple markets in the United States. The company focuses on cultivation, production, and distribution of cannabis products, aiming to professionalize the industry through a consumer-packaged goods approach.
In its latest earnings report for the third quarter of 2025, Cresco Labs reported a revenue of $165 million and an operating cash flow of $6 million. Despite a net loss of $22 million, the company maintained its market leadership and highlighted its strategic initiatives, including debt refinancing and expansion into new markets.
Key financial metrics from the report include a gross profit of $79 million and an adjusted EBITDA of $40 million, with an adjusted gross margin of 48.8% and an adjusted EBITDA margin of 24.1%. The company also announced its expansion plans with new dispensaries in Ohio and Kentucky, and a product launch in Germany, which are expected to drive future growth.
Looking ahead, Cresco Labs is positioning itself to lead in the evolving cannabis market through scale, efficiency, and disciplined execution. The company’s management remains optimistic about creating long-term shareholder value by leveraging its core assets and operational excellence.